JP2023516235A5 - - Google Patents

Info

Publication number
JP2023516235A5
JP2023516235A5 JP2022529942A JP2022529942A JP2023516235A5 JP 2023516235 A5 JP2023516235 A5 JP 2023516235A5 JP 2022529942 A JP2022529942 A JP 2022529942A JP 2022529942 A JP2022529942 A JP 2022529942A JP 2023516235 A5 JP2023516235 A5 JP 2023516235A5
Authority
JP
Japan
Prior art keywords
alkyl
oxo
decane
diazaspiro
cyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022529942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516235A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/062890 external-priority patent/WO2021113362A1/en
Publication of JP2023516235A publication Critical patent/JP2023516235A/ja
Publication of JP2023516235A5 publication Critical patent/JP2023516235A5/ja
Pending legal-status Critical Current

Links

JP2022529942A 2019-12-03 2020-12-02 Sstr5アンタゴニスト Pending JP2023516235A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943099P 2019-12-03 2019-12-03
US62/943,099 2019-12-03
PCT/US2020/062890 WO2021113362A1 (en) 2019-12-03 2020-12-02 Sstr5 antagonists

Publications (2)

Publication Number Publication Date
JP2023516235A JP2023516235A (ja) 2023-04-19
JP2023516235A5 true JP2023516235A5 (cg-RX-API-DMAC7.html) 2023-12-08

Family

ID=76221934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022529942A Pending JP2023516235A (ja) 2019-12-03 2020-12-02 Sstr5アンタゴニスト

Country Status (10)

Country Link
US (3) US20230041621A1 (cg-RX-API-DMAC7.html)
EP (3) EP4073075A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023516235A (cg-RX-API-DMAC7.html)
CN (1) CN115380036A (cg-RX-API-DMAC7.html)
AR (1) AR120652A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020398874A1 (cg-RX-API-DMAC7.html)
CA (1) CA3163243A1 (cg-RX-API-DMAC7.html)
TW (1) TW202134248A (cg-RX-API-DMAC7.html)
UY (1) UY38976A (cg-RX-API-DMAC7.html)
WO (3) WO2021113363A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
CA3227879A1 (en) * 2021-07-30 2023-02-02 TAE Life Sciences Borylated amino acid compositions comprising bts and bts(ome) for use in boron neutron capture therapy and methods thereof
CN116789570B (zh) * 2022-03-14 2026-01-27 长沙理工大学 磺酰胺脱氨制备磺酸衍生物的方法
WO2024204277A1 (ja) 2023-03-27 2024-10-03 株式会社スコヒアファーマ 成長ホルモン分泌促進剤
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
TW202606664A (zh) * 2024-04-19 2026-02-16 美商美國禮來大藥廠 升糖素受體促效劑及其作為療法之用途
WO2025222000A1 (en) * 2024-04-19 2025-10-23 Eli Lilly And Company Substituted 1,1'-biphenyl compounds as glucagon receptor agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0214967A (pt) * 2001-12-14 2005-05-10 Novo Nordisk As Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente
ATE521610T1 (de) * 2003-09-10 2011-09-15 Virochem Pharma Inc Spiroverbindungen und -verfahren zur modulation von chemokin-rezeptor-aktivität
US7709642B2 (en) * 2004-06-25 2010-05-04 Virochem Pharma, Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
CA2615656A1 (en) * 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
KR101117931B1 (ko) * 2006-08-15 2012-04-12 에프. 호프만-라 로슈 아게 페닐, 피리딘 및 퀴놀린 유도체
WO2008030412A2 (en) * 2006-09-07 2008-03-13 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
TW201006816A (en) * 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
WO2010129729A1 (en) * 2009-05-07 2010-11-11 Merck Sharp & Dohme Corp. Substituted spirocyclic amines useful as antidiabetic compounds
WO2011142359A1 (ja) * 2010-05-10 2011-11-17 日産化学工業株式会社 スピロ化合物及びアディポネクチン受容体活性化薬
JP2013529210A (ja) * 2010-05-18 2013-07-18 メルク・シャープ・エンド・ドーム・コーポレイション Sstr5アンタゴニストとしてのスピロイソオキサゾリン化合物
US8742110B2 (en) * 2010-08-18 2014-06-03 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
TW201712012A (zh) * 2015-06-16 2017-04-01 美國禮來大藥廠 2-側氧基-1,3,8-三氮雜螺[4.5]癸-3-基羧酸衍生物
WO2018024602A1 (en) * 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes

Similar Documents

Publication Publication Date Title
US20130261108A1 (en) Compositions and methods for modulating farnesoid x receptors
JP2022512482A5 (cg-RX-API-DMAC7.html)
JP5788507B2 (ja) 置換3−フェニル−1,2,4−オキサジアゾール化合物
CN103502226B (zh) 用于cetp抑制剂的环烯基芳基衍生物
US20140039007A1 (en) Compositions and methods for modulating farnesoid x receptors
CN103237795B (zh) 经取代的噁二唑化合物及其作为s1p1激动剂的用途
EA030430B1 (ru) Композиции и способы модуляции фарнезоидных х-рецепторов
EP2001844A2 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
JP2007502264A5 (cg-RX-API-DMAC7.html)
KR20150046090A (ko) 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
TW200831511A (en) Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
TW200804266A (en) Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
CN111164072A (zh) β-羟基杂环胺及其在治疗高糖血症中的用途
CN103298807A (zh) 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物
JP2004269469A (ja) ピリミジン誘導体又はその塩
DK2697219T3 (en) NEW PIPERIDINYLMONOCARBOXYLSYRER AS S1P1 receptor agonists
RU2627361C2 (ru) Биарил- или гетероциклические биарилзамещенные производные циклогексена в качестве ингибиторов сетр
JPWO2001036402A1 (ja) 新規な2−(n−シアノイミノ)チアゾリジン−4−オン誘導体
JP2020521775A5 (cg-RX-API-DMAC7.html)
JP2022542613A (ja) ヒトatglの阻害剤
TW202417426A (zh) 三氮唑類化合物及其作為lpar1拮抗劑的用途
CN103958484B (zh) 噁唑烷酮类衍生物、其制备方法及其在医药上的应用
JPH08325264A (ja) 新規2−芳香環置換−3−フェニルプロピオン酸またはアクリル酸誘導体
CN111138422B (zh) 一种用于防治红斑狼疮的药物及其制备方法
JP2012006869A (ja) ピリミジノン化合物およびその医薬用途